Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein

0301 basic medicine Cancer Research Skin Neoplasms Placenta Melanoma, Experimental Antigens, Protozoan Mice 03 medical and health sciences Pregnancy Cell Line, Tumor Human Umbilical Vein Endothelial Cells Animals Humans Molecular Targeted Therapy 0303 health sciences Chondroitin Sulfates Membrane Proteins Cell Biology Recombinant Proteins 3. Good health HEK293 Cells Hyaluronan Receptors Oncology Chondroitin Sulfate Proteoglycans Organ Specificity Female Oligopeptides
DOI: 10.1016/j.ccell.2015.09.003 Publication Date: 2015-10-13T00:57:24Z
ABSTRACT
Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (26)
CITATIONS (176)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....